BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37114273)

  • 1. Effects of Vinblastine and Vincristine on the function of chronic myeloid leukemic cells through expression of A20 and CYLD.
    Hoang NH; Huyen NT; Trang DT; Canh NX; Mao CV; Sopjani M; Vuong NB; Xuan NT
    Cell Mol Biol (Noisy-le-grand); 2022 Sep; 68(10):47-53. PubMed ID: 37114273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.
    Çalışkan C; Pehlivan M; Yüce Z; Sercan O
    Mol Biol Rep; 2017 Oct; 44(5):391-397. PubMed ID: 28840581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.
    Lee J; Zhang G; Wu X; Xu F; Zhou J; Zhang X
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2095-102. PubMed ID: 22833150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
    Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
    Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
    Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
    Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation.
    Qin R; Li K; Qi X; Zhou X; Wang L; Zhang P; Zou L
    Br J Cancer; 2014 Jul; 111(3):568-76. PubMed ID: 24937675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
    Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
    Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
    Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.